Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-09-22Clinical Trial Update: RCT of Methotrexate Added to Treatment As Usual in Schizophrenia [Phase 1]
A Phase 1 randomized trial assessed adding methotrexate to treatment as usual in schizophrenia and related disorders; the study has been com…
-
CLINICAL_TRIALS trial_result · 2015-09-22Clinical Trial Update: The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong [NA]
This completed trial evaluated the Two-Way Communication Checklist (2-COM) in schizophrenia patients presenting with first-episode psychosis…
-
CLINICAL_TRIALS trial_result · 2015-09-21Clinical Trial Update: A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia [Phase 3]
A Phase 3 follow-on study assessed the long-term safety of aripiprazole in adults with chronic schizophrenia; the trial was terminated and r…
-
CLINICAL_TRIALS trial_result · 2015-09-21Clinical Trial Update: The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes [Phase 1, Phase 2]
A terminated Phase 1/2 clinical trial evaluated the effects of cannabis use in people with schizophrenia; results were posted in 2015. The s…
-
FDA approval · 2015-09-18FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for CLOZARIL (clozapine) submitted by HLS Therapeutics (USA), Inc., signaling an update to the produ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-09-17FDA Approved: VRAYLAR — Original Application (Allergan, Inc.)
The FDA approved VRAYLAR (cariprazine) under the original application NDA204370 for the treatment of schizophrenia and manic or mixed episod…
-
FDA approval · 2015-09-17FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
CLINICAL_TRIALS research · 2015-09-17Clinical Trial Update: The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism [NA]
A clinical trial update from Shanghai Mental Health Center examining whether omega-3 fatty acids influence violence/aggression in patients w…
-
FDA approval · 2015-09-15FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Clozapine submitted by Mylan Pharmaceuticals Inc.
-
FDA approval · 2015-09-15FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
The FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics (USA), Inc., updating/expanding the produ…
-
FDA approval · 2015-09-15FDA Tentative Approval: CLOZAPINE — Original Application (Mylan Pharmaceuticals Inc.)
FDA issued tentative approval for a generic Clozapine from Mylan Pharmaceuticals Inc. under ANDA201824, allowing U.S. marketing for approved…
-
CLINICAL_TRIALS trial_result · 2015-09-11Clinical Trial Update: Influence of Emotion in a Test Run Forgetfulness [NA]
The clinical trial evaluating the influence of emotion on a test task related to forgetfulness has completed. It enrolled individuals with s…
-
CLINICAL_TRIALS trial_result · 2015-09-10Clinical Trial Update: Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade [NA]
Clinical trial update reporting results on the neurocognitive effects of ziprasidone and its relation to working memory and dopamine blockad…
-
CLINICAL_TRIALS trial_result · 2015-09-09Clinical Trial Update: Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia [NA]
A completed clinical trial evaluating the effects of repetitive transcranial magnetic stimulation (rTMS) on cigarette smoking behavior and c…
-
FDA approval · 2015-09-04FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for quetiapine fumarate from Hikma Pharmaceuticals USA, indicating approval of changes to the pr…
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia [Phase 2]
Phase 2 study evaluating the efficacy, safety, and tolerability of oral OPC-34712 in combination with aripiprazole for acute schizophrenia; …
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects [Phase 1]
Phase 1 clinical trial evaluating OPC-34712 in subjects with normal hepatic function and hepatic impairment completed; results were posted i…
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Specific Cognitive Remediation for Schizophrenia [NA]
This entry notes the completion of a clinical trial evaluating a specific cognitive remediation approach for schizophrenia.
-
CLINICAL_TRIALS research · 2015-09-01Clinical Trial Update: Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia [Phase 2]
This document reports a Phase 2 clinical trial evaluating repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst s…
-
CLINICAL_TRIALS research · 2015-09-01Clinical Trial Update: Effects of Transcranial Direct Current Stimulation in Individuals With Schizophrenia [NA]
A Johns Hopkins–sponsored clinical trial evaluating transcranial direct current stimulation for schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2015-09-01Clinical Trial Update: Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder
A completed clinical trial evaluated auditory brainstem response as a diagnostic tool for schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2015-08-31Clinical Trial Update: A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688) [Phase 3]
Clinical trial update reporting the completion of a Phase 3 study evaluating the efficacy and safety of asenapine in adults with acute exace…
-
FDA approval · 2015-08-27FDA Approved: RISPERIDONE — Supplemental Application (Ajanta Pharma USA Inc.)
The FDA approved a supplemental application for risperidone from Ajanta Pharma USA Inc., indicating an approved regulatory action for this p…
-
CLINICAL_TRIALS trial_result · 2015-08-26Clinical Trial Update: Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238) [Phase 3]
Phase 3 long-term study of asenapine in adults with residual schizophrenia or treatment-refractory schizophrenia; results were posted in 201…
-
CLINICAL_TRIALS trial_result · 2015-08-25Clinical Trial Update: Effects of Varenicline on Plasticity in Schizophrenia [Phase 2]
Phase 2 trial completed evaluating varenicline for effects on plasticity in schizophrenia.